• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Biogen (BIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next

    Simply Wall St·07/30/2026 21:18:53
    Listen to the news
    • Biogen Inc. has reported its second-quarter 2026 results, with revenue rising to US$2.74 billion from US$2.65 billion a year earlier while net income dropped sharply to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33.
    • Behind the headline revenue beat and upgraded full-year guidance, Biogen’s expanding growth portfolio and Apellis acquisition are increasingly offsetting pressure on legacy multiple sclerosis therapies.
    • We’ll now examine how Biogen’s revenue beat and raised guidance, driven by new therapies, reshapes the company’s long-term investment narrative.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    Biogen Investment Narrative Recap

    To own Biogen today, you need to believe its newer neurology and rare disease drugs can increasingly compensate for pressure on legacy multiple sclerosis products. The latest quarter supports that shift, with growth therapies and the Apellis portfolio driving a revenue beat and upgraded 2026 guidance, even as GAAP earnings fell sharply on one off items. Near term, execution on launches like LEQEMBI looks like the key catalyst, while sustained profitability pressure remains the central risk.

    Among recent announcements, the FDA’s approval of at home subcutaneous initiation for LEQEMBI stands out in light of Q2 results. It directly reinforces the growth portfolio that outpaced the MS franchise this quarter, and could influence how quickly physicians and patients adopt Alzheimer’s treatment options. Together with the Apellis acquisition, it underpins Biogen’s effort to pivot toward higher growth areas while legacy MS revenue faces ongoing competition and pricing pressure.

    However, beneath the improving growth story, investors should be aware of the risk that profitability continues to lag revenue growth, especially if...

    Read the full narrative on Biogen (it's free!)

    Biogen’s narrative projects $10.6 billion revenue and $2.3 billion earnings by 2029.

    Uncover how Biogen's forecasts yield a $227.59 fair value, a 9% upside to its current price.

    Exploring Other Perspectives

    BIIB 1-Year Stock Price Chart
    BIIB 1-Year Stock Price Chart

    By contrast, the most bearish analysts were assuming roughly flat revenue around US$9.8 billion and earnings of about US$1.8 billion by 2029, so this quarter’s mix of modest growth and weaker GAAP profitability could easily change how pessimists and optimists alike frame Biogen’s execution and pricing risks.

    Explore 5 other fair value estimates on Biogen - why the stock might be worth 22% less than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

    Looking For Alternative Opportunities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.